Literature DB >> 31917991

Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom.

Olafur S Palsson1, William Whitehead2, Hans Törnblom3, Ami D Sperber4, Magnus Simren5.   

Abstract

BACKGROUND & AIMS: Little is known about the population prevalence or demographic distributions of Rome IV functional bowel disorders (FBDs) or their effects on quality of life. We examined these in a multinational survey.
METHODS: We analyzed data from a population-based survey of adults in the United States, Canada, and United Kingdom (5931 valid responders; 49.2% female; mean age, 47.4 years; range, 18-92 years). The survey included the Rome IV Diagnostic Questionnaire, Rome III irritable bowel syndrome (IBS) and constipation questions, and the SF-8 quality of life questionnaire.
RESULTS: The prevalence values of census-adjusted Rome IV FBDs were similar among the 3 countries; ranges were: 4.4%-4.8% for IBS, 7.9%-8.6% for functional constipation, 3.6%-5.3% for functional diarrhea, 2.0%-3.9% for functional bloating or distention, 1.1%-1.9% for opioid-induced constipation, 7.5%-10.0% for unspecified FBDs, and 28.6%-31.7% for any Rome IV FBD. FBDs were less common in older individuals, and all except functional diarrhea were more common in women. IBS was only half as prevalent by Rome IV as by Rome III criteria (4.6% vs 9.0% overall), primarily due to higher Rome IV minimum pain frequency. Functional diarrhea and functional constipation were more prevalent by Rome IV than Rome III criteria. Subjects with FBD had significant reductions in quality of life and reported more gastrointestinal doctor consultations than other subjects.
CONCLUSIONS: More than 1 in 4 adults in the general population meet the Rome IV criteria for FBDs. These disorders affect quality of life and increase use of gastrointestinal health care. The switch from Rome III to Rome IV criteria reduces the prevalence of IBS by half, but increases the prevalence of functional constipation and functional diarrhea.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abdominal Pain; Epidemiology; Europe; GI Disorder

Year:  2020        PMID: 31917991     DOI: 10.1053/j.gastro.2019.12.021

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  54 in total

1.  Predicting the micromechanics of embedded nerve fibers using a novel three-layered model of mouse distal colon and rectum.

Authors:  Yunmei Zhao; Bin Feng; David M Pierce
Journal:  J Mech Behav Biomed Mater       Date:  2022-01-20

Review 2.  Global burden of irritable bowel syndrome: trends, predictions and risk factors.

Authors:  Christopher J Black; Alexander C Ford
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-15       Impact factor: 46.802

Review 3.  Dietary Fibre Intervention for Gut Microbiota, Sleep, and Mental Health in Adults with Irritable Bowel Syndrome: A Scoping Review.

Authors:  Ran Yan; Lesley Andrew; Evania Marlow; Kanita Kunaratnam; Amanda Devine; Ian C Dunican; Claus T Christophersen
Journal:  Nutrients       Date:  2021-06-23       Impact factor: 5.717

Review 4.  Best management of irritable bowel syndrome.

Authors:  Christopher J Black; Alexander Charles Ford
Journal:  Frontline Gastroenterol       Date:  2020-05-28

Review 5.  Understanding the physiology of human defaecation and disorders of continence and evacuation.

Authors:  Paul T Heitmann; Paul F Vollebregt; Charles H Knowles; Peter J Lunniss; Phil G Dinning; S Mark Scott
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-09       Impact factor: 46.802

Review 6.  Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.

Authors:  Hannibal Person; Laurie Keefer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-12-14       Impact factor: 5.067

7.  Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome.

Authors:  Christopher V Almario; Samuel Eberlein; Carine Khalil; Brennan M R Spiegel
Journal:  Neurogastroenterol Motil       Date:  2021-04-02       Impact factor: 3.598

8.  Leveraging 16S rRNA Microbiome Sequencing Data to Identify Bacterial Signatures for Irritable Bowel Syndrome.

Authors:  Yuxia Liu; Wenhui Li; Hongxia Yang; Xiaoying Zhang; Wenxiu Wang; Sitong Jia; Beibei Xiang; Yi Wang; Lin Miao; Han Zhang; Lin Wang; Yujing Wang; Jixiang Song; Yingjie Sun; Lijuan Chai; Xiaoxuan Tian
Journal:  Front Cell Infect Microbiol       Date:  2021-06-11       Impact factor: 5.293

9.  Detection of cancers and advanced adenomas in asymptomatic participants in colorectal cancer screening: a cross-sectional study.

Authors:  Anna Lisa Schult; Edoardo Botteri; Geir Hoff; Kristin R Randel; Eirin Dalén; Sigrun Losada Eskeland; Øyvind Holme; Thomas de Lange
Journal:  BMJ Open       Date:  2021-07-01       Impact factor: 2.692

10.  Illness perception and health care use in individuals with irritable bowel syndrome: results from an online survey.

Authors:  Juliane Schwille-Kiuntke; Solveig Lu Rüdlin; Florian Junne; Paul Enck; Katja Brenk-Franz; Stephan Zipfel; Monika A Rieger
Journal:  BMC Fam Pract       Date:  2021-07-19       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.